The Diabetes Beat

  • Is Inhaled Insulin a 'Game Changer'? The anticipated arrival of Afrezza, a new insulin product delivered via inhaler, is generating both excitement and skepticism.
  • What if Avandia Is Safe After All? A much-maligned diabetes drug may get a shot at vindication at an upcoming hearing of the US Food and Drug Administration.
  • Be Wise When Choosing Wisely A national campaign to limit unnecessary medical practices may carry its own inherent risks.
  • A 2-by-4 'Cure' for Type 2 Diabetes? The FDA's approval of alogliptin presents interesting new treatment options for type 2 diabetes.
  • Alogliptin's Approval Woes Alogliptin has had a tortuous time in seeking FDA approval, but even if it succeeds, who will use it?
  • Sulfonylureas in Diabetes: Why So Controversial? Despite continuing concerns about sulfonylureas in the management of type 2 diabetes, many clinicians remain unwilling to give up this treatment option.